Poolbeg Pharma #POLB – Major milestone reached as POLB 001 human challenge clinical trial ready to commence
20 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims […]
Poolbeg Pharma #POLB to engage with key international stakeholders at European Melioidosis Congress as it develops an intramuscular Melioidosis vaccine candidate
11 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a […]
Poolbeg Pharma #POLB presenting at LSX Leaders event
Today Poolbeg Pharma #POLB will be attending the LSX Leaders event & CEO Jeremy Skillington will be presenting the Poolbeg Pharma story, including how we are aspiring to become a one-stop-shop for Big Pharma seeking mid-stage products to license or acquire.
Poolbeg Pharma #POLB – POLB 001 Clinical Development – Clinical Trial Agreement Signed
31 March, 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) announces that it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001, which is due to commence in June […]
Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States
30 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that trading in the Company’s Ordinary Shares of nominal value of £0.02 each (“Ordinary Shares”) will commence today on the OTCQB Venture Market in the United States. The […]
Poolbeg Pharma #POLB – Growing a Capital Light Company. CEO Jeremy Skillington talks to Alan Green
Poolbeg Pharma #POLB – CEO Jeremy Skillington talks to Alan Green, and explains the ‘capital light’ model used by the company to grow the business. Jeremy talks about the three licensing deals signed by the company over the past few months, including the option agreement to licence MelioVac, the tie up with AnaBio Technologies and today’s […]
Poolbeg Pharma #POLB CEO Jeremy Skillington talks to BRR Media
Poolbeg Pharma #POLB CEO Jeremy Skillington talks to BRR Media and outlines the progress made in the 5 months post IPO, along with group plans for 2022.
Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green
Poolbeg Pharma #POLB Exec Chairman Cathal Friel and CEO Jeremy Skillington talk to Alan Green about the company’s ‘capital light’ business model. We discuss the POLB 001 asset, spun out of Open Orphan #ORPH, data samples, the PredictViral and vaccine discovery platforms plus further pipeline products. Cathal discusses the company cash position, and Jeremy highlights […]
#POLB Poolbeg Pharma – PredictViral™ Patent update
4 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new patent filings for its PredictViral™ platform that estimates disease severity and contagiousness in people who are recently infected with a respiratory virus. Expanding on existing […]
Poolbeg Pharma #POLB – Admission to AIM and First day of trading
Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker […]